Background. Empirical combination therapy is recommended for patients with known or suspected Pseudomonas aeruginosa (PA) infection as a means to decrease the likelihood of administering inadequate antimicrobial treatment, to prevent the emergence of resistance, and to achieve a possible additive or even synergistic effect.
The rapidity with which patients succumb to severe pseudomonal infections is disturbing, as up to 50% of patients with PA bacteremia die within the first 24-72 hours; therefore, prompt administration of effective treatment seems essential.
The most recent Surviving Sepsis guidelines [1] recommend empirical combination therapy, particularly for patients with known or suspected Pseudomonas infections, as a means to decrease the likelihood of administering inadequate empirical antimicrobial therapy. However, it has not been clearly established whether adequate empirical antimicrobial therapy truly improves survival in cases of suspected PA bacteremia [2] [3] [4] [5] .
One of the potential advantages of using combination therapy is the increased likelihood that the infecting pathogen will be susceptible to at least 1 of the components of the antibiotic regimen. However, the limited number of drugs available for treatment of PA infections, because of the intrinsic resistance of the microorganism to multiple antibiotics, increases the complexity of management. Although empirical use of combinations of antibiotics may quickly achieve adequate activity against resistant strains, some authors have questioned this strategy. Unfortunately, none of the studies on PA infection have included series of treated patients with multidrug-resistant (MDR) PA. Several meta-analyses indicate that combination antimicrobial therapy does not reduce mortality in patients with gram-negative bacteremia [6, 7] . One of these reports found a survival benefit with the use of combination therapy for PA bacteremia [8] ; however, other authors [9] have raised doubts about the results of this study because it included aminoglycoside monotherapy as adequate, and the benefit was no longer significant when the odds ratio for mortality was recalculated after excluding this therapy. Examining the same issue in patients with ventilator-associated pneumonia [10] [11] [12] , monotherapy demonstrated similar outcomes to those achieved with combination therapy.
In view of conflicting data regarding the beneficial effect of combination therapy in reducing mortality, we present an analysis of a large prospective cohort of PA bacteremia [13] with about 30% of MDR strains. The main goal was to determine whether adequate combination antimicrobial therapy directed against PA was associated with lower 30-day mortality than monotherapy.
MATERIALS AND METHODS

Setting and Design
A post hoc analysis of patients with PA bacteremia carried out in 10 public hospitals located in 4 areas of Spain (Andalusia, the Balearics, Cantabria, and Catalonia) was designed to evaluate the impact of adequate combination therapy on clinical outcome in patients with monomicrobial PA bacteremia. All adult patients with PA bacteremia were recruited prospectively through daily reviews of blood cultures [13] . Patients were monitored until day 30 after bacteremia and the cases were censored from analysis because of either death or transfer to another hospital. Only the first bacteremia episode for each patient was included in the analysis. The study was approved by the local ethics committees of the participating centers.
Variables and Definitions
The following data were recorded: age and sex; comorbidities and severity of underlying diseases calculated using the Charlson comorbidity index [14] , and severity of illness estimated by the Simplified Acute Physiology Score (SAPS II) in intensive care unit patients [15] ; the presence of neutropenia (absolute granulocyte count of <500/mL) and the use of immunosuppressive therapy (chemotherapy, radiotherapy, and/or immunosuppressive drugs during the bacteremia presentation); source of bacteremia; severity of acute illness at presentation according to the Pitt bacteremia score [16] ; presence of septic shock, defined as sustained hypotension despite adequate fluid replacement and requiring inotropic support, and multiorgan dysfunction syndrome (MODS) considered if a patient had at least 2 organ system dysfunctions as a consequence of bacteremia, at bacteremia presentation and at 48 hours [17] ; and antimicrobial treatment received. The source of bacteremia was divided into 2 categories: low risk (urinary tract, vascular catheter, and pancreaticobiliary origin) and high risk (all other sources) [18] .
Microbiological Studies
The blood isolates were studied at the participating centers and sent to the reference laboratory (Servicio de Microbiología, Hospital Universitario Marqués de Valdecilla, Santander, Spain). PA strains were tested for their antimicrobial susceptibilities by individual laboratories using standard techniques. In the reference laboratory, the antibiotic susceptibilities of 603 available isolates were confirmed by broth microdilution, according to the Clinical and Laboratory Standards Institute (CLSI) guidelines [19] . The following antimicrobial agents were tested: aztreonam, ceftazidime, cefepime, piperacillin, piperacillin-tazobactam, imipenem, meropenem, gentamicin, tobramycin, amikacin, levofloxacin, ciprofloxacin, colistin, and fosfomycin. Clinical categories were determined according to the breakpoints defined by the European Committee on Antimicrobial Susceptibility testing (EUCAST) criteria [20] , except for fosfomycin, for which CLSI breakpoints for enterobacteria were applied. MDR and extensively drug-resistant PA were defined according to a recent consensus document [21] , considering the agents indicated above.
Antimicrobial Treatment Definitions
Empirical therapy was considered when an antimicrobial regimen was administered within 24 hours of extraction of the blood sample, and before susceptibility was known; a therapy that was continued or commenced on the day that antibiogram results were reported was considered definitive. Antimicrobial therapy was considered adequate when the PA isolate was susceptible to the antimicrobial prescribed and the dose was in accordance with current medical standards. Therapy referred to the administration of antimicrobial agents to which the causative microorganism was resistant in vitro, or to the lack of a treatment, was considered inadequate [18] . Aminoglycoside monotherapy was considered inadequate treatment for PA pneumonia; in contrast, administration of an active aminoglycoside for urinary tract infections was considered to be adequate monotherapy.
Combination therapy was defined as adequate if the strain was susceptible to both antipseudomonal drugs given simultaneously; treatment with an active antipseudomonal antimicrobial was considered single-drug therapy. We distinguished the following categories of empirical treatment: adequate empirical combination therapy (AECT), adequate empirical single-drug therapy (AESD), and inadequate empirical therapy (IET). In addition, adequate or inadequate antimicrobial definitive therapy was considered according to the results of the minimum inhibitory concentration (MIC) microdilution reference method. Thus, 3 categories of definitive treatment were observed on the basis of MIC susceptibility findings: adequate definitive combination therapy (ADCT), adequate definitive single-drug therapy (ADSD), and inadequate definitive therapy (IDT).
Statistical Analysis
Patients for whom data on antibiotic susceptibility were missing were excluded from the analysis. Analyses were performed on an intent-to-treat basis and were limited to treatments received (1) within 24 hours of extraction of the blood sample and before susceptibility was known (empirical); and (2) therapy administered according to results of the antibiogram (definitive).
Survival curves were constructed by means of the KaplanMeier method and log-rank test to estimate the risk of death according to empirical antimicrobial therapy stratification. The outcome evaluated was death, and the date of the initial P. aeruginosa isolate was considered as time 0. To control for confounding effects of combination therapy (exposure) on time to mortality (30-day outcome), we used multivariate adjusted hazard ratios (AHRs) with Cox regression. Due to the baseline imbalances between patients, a propensity score for receiving combination treatment was added to the model. The propensity score, probability of receiving combination treatment, was calculated using multivariate logistic regression model and included the following variables: Charlson index, Pitt score, PA susceptibility, source risk bacteremia, and immunosuppression therapy. The model showed a P value of .88 for the Hosmer-Lemeshow test and an area under the receiver operating characteristic curve of 0.77, showing good predictive ability. All statistical analyses were performed with the SPSS software package version 15.0.
RESULTS
Epidemiological and Clinical Characteristics
During the 2-year study, 632 episodes of PA bacteremia were prospectively included [13] . Twenty-nine patients in whom data on antibiotic susceptibility were missing and 10 who presented a second episode were excluded. The final cohort comprised 593 patients with a single episode of PA bacteremia. The clinical and epidemiological characteristics are shown in Table 1 .
Six patients with PA bacteremia did not receive antibiotics: in 5, the origin was intravenous catheter related, and they were treated with catheter removal alone; the other was an intraabdominal abscess, and it was treated with nonsurgical drainage. All patients but one with intravenous catheter-related bacteremia were alive at 30 days; the other patient was transferred to another center 19 days after bacteremia onset.
Among the 593 patients, 332 (56%) had received adequate empirical antimicrobial therapy and 261 (44%) inadequate therapy ( Table 2 ). Adequate empirical therapy was stratified into AESD (266 patients [80%]) and AECT (66 patients [20%]). Among the 266 patients who received AESD, 29 (11%) were treated with 2 drugs simultaneously, but only 1 was active. When these patients were excluded because of the possible additive or synergistic action of this treatment, no effect on the overall AESD results was observed. AESD patients received the following treatments: 88 (33%) piperacillin-tazobactam, 71 (27%) carbapenems, 54 (20%) antipseudomonal cephalosporins, 25 (9%) fluoroquinolones, and 22 (8%) aminoglycosides; of the remaining 6 patients, 3 received monobactam and 3 colistin. Among the 66 patients treated with AECT, β-lactam and aminoglycosides (43/66 [65%]) and β-lactam and fluoroquinolones (18/ 66 [27%]) were the most frequent antimicrobial combinations; of the remaining patients, 2 received fluoroquinolones and aminoglycoside, 2 colistin and β-lactam, and one 2 β-lactams.
The 30-day mortality rate was 30% (176 patients), and there were 76 deaths (13%, representing 43% of all patients who died) during the first 48 hours. The unadjusted probabilities of survival until day 30 ( Figure 1 ) were 69.4% (95% confidence interval [CI], 59.1%-81.6%) for the patients who received AECT, 73.5% (95% CI, 68.4%-79.0%) in the AESD group, and 66.7% (95% CI, 61.2%-72.7%) for patients treated with IET (P = .17, log-rank test).
Outcome: 30-Day Mortality
Empirical Antimicrobial Therapy Unadjusted 30-day mortality for patients with PA bacteremia is shown in Table 2 . Cox regression model, including propensity score plus variables associated with mortality-namely, highrisk bacteremia, presentation with shock, Charlson score, and PA susceptibility-showed no association of the AESD group (AHR, 1.17; 95% CI, .70-1.96; P = .54) with 30-day mortality, although patients treated with IET (AHR, 1.70; 95% CI, .99-2.92; P = .052) showed a statistically significant risk (Table 3) .
Interestingly, patients who presented a high Pitt bacteremia score had more frequently received AECT. The probabilities of survival adjusted by the Pitt score were 90.9% (95% CI, 79.7%-100%) for the AECT group, 83.9% (95% CI, 78.3%-89.9%) for AESD, and 84.3% (95% CI, 78.7%-90.3%) for IET in patients with Pitt score <2; in patients with Pitt score ≥2, cumulative survival was 58.6% (95% CI, 45.6%-75.3%) for the AECT group, 58.7% (95% CI, 50.2%-68.7%) for AESD, and (26) 75 (29) .45 20 (28) 85 (25) 19 (27) .84
Heart disease 14 (21) 42 (16) 53 (20) . 33 14 (20) 59 (17) 15 (21) .72
Chronic renal failure 4 (6) 46 (17) 45 (17) .065 5 (7) 60 (18) 12 (17) .082 Hematologic malignancy 24 (36) 43 (16) 23 (9) <.001 19 (27) 46 (14) 3 (4) .001
Chronic lung disease 13 (20) 39 (15) 34 (13) .38 12 (17) 42 (12) 12 (17) .42
Chronic neurologic disease 4 (6) 24 (9) 15 (6 41.0% (95% CI, 32.5%-51.5%) for IET (Figure 2) . By multivariate analysis, the risk of 30-day mortality was also similar between the AESD group (AHR, 1.05; 95% CI, .61-1.80; P = .85) and the AECT group; moreover, IET showed a higher risk (AHR, 1.65; 95% CI, .94-2.88; P = .077). A subgroup analysis was performed of 115 (19.4%) patients with presence of septic shock at bacteremia presentation. The probabilities of survival were 56.0% (95% CI, 39.6%-79.3%) for the AECT group, 55.1% (95% CI, 42.8%-70.9%) for AESD, and 39.0% (95% CI, 26.6%-57.2%) for IET. After adjustment for the propensity score and variables associated with mortality, the 30-day mortality did not differ between patients receiving AECT and those receiving AESD therapy (AHR, 0.88; 95% CI, .42-1.87; P = .74).
In addition, patients who presented a high-risk bacteremia had more frequently received AECT than patients with low risk (27% vs 12%; P < .001). Regarding high-risk bacteremia, the probabilities of survival were 56.9% (95% CI, 44.3%-73.1%) for AECT and 63.7% (95% CI, 55.8%-72.8%) for the AESD group (P = .30, log-rank test), without difference in 30-day mortality between both treatments (AESD: AHR, 0.93; 95% CI, .54-1.59; P = .78).
Finally, among the patients with non-MDR PA bacteremia, the probabilities of survival were 70.9% (95% CI, 60.2%-83.6%) for the AECT group, 77.3% (95% CI, 71.8%-83.2%) for the AESD group, and 68.0% (95% CI, 60.3%-76.7%) for IET (P = .094, log-rank test). In patients with non-MDR-PA infections, the adjusted risk of 30-day mortality was similar in the AESD group (AHR, 1.06; 95% CI, .59-1.89; P = .83) and the AECT group; moreover, IET showed a major risk (AHR, 2.06; 95% CI, 1.12-3.83; P = .021).
Definitive Antimicrobial Therapy Of the 593 patients, 481 were still alive and under follow-up at the time when definitive antimicrobial therapy was administered. Seventy-one (15%) patients received ADCT, 339 (70%) ADSD, and 71 (15%) IDT (Table 2) . Among those receiving ADCT, 35 (49%) received β-lactam and aminoglycosides, 26 (37%) received β-lactam and fluoroquinolones, 7 (10%) received fluoroquinolones and aminoglycoside, and the remaining 3 patients received colistin and aminoglycoside. In 15 patients (21%) treated with ADCT, empirical combination therapy was unmodified. In the 71 patients who received IDT, 50 (70%) had a low risk source of bacteremia (30 urinary tract origin, 12 intravascular catheter origin, and 8 biliar origin), and 21 (30%) had a high-risk source (9 respiratory tract, 6 unknown, 4 surgical site infection, and 2 soft tissue). Eleven (17%) of these patients died: 3 with respiratory tract infection, 2 with bacteremia of unknown origin, 2 with vascular catheter origin, 2 with urinary tract infection, and 1 each with biliar and soft tissue.
Crude analysis showed that the ADSD group had a similar risk of death (Table 4 ). Multivariate analysis, adjusted for the propensity score and variables associated with mortality (highrisk bacteremia, Pitt score, shock/MODS at 48 hours, and PA susceptibility), showed that the 30-day mortality did not differ between patients receiving ADSD (AHR, 1.34; 95% CI, .73-2.47; P = .35) and those who received ADCT (Table 3) .
DISCUSSION
The present study analyzed the impact of adequate empirical and definitive combination antimicrobial therapy on mortality rates in a large prospective series of patients with PA bloodstream infections. We were unable to demonstrate a significant association between adequate combination antibiotic therapy and survival in these patients.
In evaluating the possible influence of antimicrobial therapy on outcomes, the most important drawback of observational studies is that the therapeutic regimen is not selected by chance. Many patient characteristics which by themselves are expected to have an impact on prognosis may simultaneously influence the results owing to frequent administration of combination therapy to critically ill patients. In fact, our data suggest that combination therapy tended to be administered to patients with more severe clinical presentation (67% with Pitt score ≥2 vs 7% with Pitt score <2) and high-risk source of bacteremia (27% vs 12%). Moreover, we no found beneficial effect of AECT on the probabilities of survival until day 30 adjusted by Pitt score. These results were similar to those obtained in a recent retrospective study [22] in which combination therapy was not associated with survival advantage among severely ill patients with bacteremia caused by gram-negative bacilli. In addition, recommending combination therapy for patients with Pseudomonas infections as a cause of severe sepsis is standard practice in many hospitals. However, the data supporting its use are by no means clear. Some reports [23] [24] [25] suggest that the beneficial effect is restricted to critically ill patients with septic shock. Moreover, a recent randomized study [26] demonstrated that combination therapy did not reduce organ dysfunction in patients with severe sepsis caused by different pathogens. Our specific subgroup analysis of patients with shock corroborated this result, as in the whole series, empirical combination therapy was not associated with a reduction of 30-day mortality in severely ill patients.
Many clinical studies, particularly in patients with bacteremia [2, 3, [27] [28] [29] [30] [31] and ventilator-associated pneumonia [10] [11] [12] 32] , have attempted to clarify this issue. Their conclusions are often conflicting, and most studies failed to show any benefits of combination therapy on mortality when examining only adequate therapy. Indeed, our study shows that the choice between combination therapy and single-drug therapy does not affect outcome. In contrast to the results of a retrospective cohort of PA bacteremia [28] , we did not find that empirical combination antimicrobial therapy influenced 30-day mortality.
In our study, it was noted that IDT showed no association with 30-day mortality, and although the difference was not statistically significant, IDT showed a lower risk of overall mortality than ADCT. We cannot provide an adequate explanation for this last finding, although other studies have also reported similar results [33, 34] . Among other possible factors are the susceptibility breakpoints used, as those of EUCAST tend to be stricter than those of CLSI ( particularly before the update of the CLSI breakpoints in 2012 [19] ). Thus, marginal in vivo antimicrobial activity in some cases who received inadequate treatment cannot be ruled out. Finally, in this regard, one aspect of our series should be noted; 15% of patients received definitive treatment considered inadequate, but were within the susceptible range according to antimicrobial susceptibilities established by participating individual laboratories and according to earlier CLSI criteria. Despite the notoriety of PA, pseudomonal bacteremia is not particularly common; as a result, large, randomized, prospective studies are difficult to perform. In this study, the observational nature of the data is the major limitation, because choice of combination therapy vs monotherapy was at the physician's discretion. This may have influenced the results, and we cannot rule out the possibility that estimates of treatment effects were biased by an imbalance associated with the treatment choices that was not accounted for in the multivariate analysis; thus, an adjustment using propensity score was performed for attempts to compensate for the problem created by the unequal chances for receiving treatment. In addition, despite the large sample size, its statistical power is limited; specifically, our sample offers sufficient statistical power (80%) to identify differences above 20% with an α level of .05. However, to our knowledge, this is the largest prospective series published to date comparing empirical and definitive combination therapy with monotherapy on PA bloodstream infections. Finally, we did not monitor the emergence of resistance and adverse events, which are potential advantages and negative consequences of the combination therapy; unfortunately, our study was not designed to address these issues.
In conclusion, in this multicenter study, treatment with combined therapy did not reduce overall mortality risk compared with single-drug therapy. However, a survival advantage cannot be ruled out, because the sample size is not large enough to identify small differences between the types of treatment. These results are in agreement with previous studies and suggest that adequate combination therapy was not a decisive factor in the prognosis of PA bacteremia. This information could help prevent the overuse of antibiotics and may also guide antibiotic policy by allowing a more judicious use of the few antimicrobial options available.
Notes
